Blood and Marrow Transplant (BMT), Leukemia, Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin
Conditions
Brief summary
To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.
Detailed description
To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma
Interventions
Sponsors
Stanford University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 50 Years
Healthy volunteers
No
Inclusion criteria
HLA identical donor * adequate organ function * other life threatening disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | october 2009 |
| disease free survival | October 2009 |
Secondary
| Measure | Time frame |
|---|---|
| early and late toxicities of the treatment regimen | October 2009 |
Countries
United States
Outcome results
None listed